Gennex Laboratories Ltd
GENNEX · NSEon the next trading day
Valuation
Blended fair value using DCF and peer comparison methods.
See if Gennex Laboratories Ltd is undervalued
Unlock intrinsic value for 4,800+ Indian stocks — free.
Sign in or create free accountThe intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Gennex Laboratories Ltd GENNEX · you | ₹246 Cr | 16.4× | 1.5× | — | 8.9% | 0.1% | — |
| Sector median | — | 44.1× | 3.1× | 23.0× | 12.5% | 3.6% | 11.6% |
| Panacea Biotec Limited PANACEABIO | ₹2,434 Cr | — | 3.0× | — | -0.6% | -0.8% | 11.6% |
| KMC Speciality Hospitals India Limited KMCSHIL | ₹2,166 Cr | 38.8× | 14.2× | — | 36.5% | 0.2% | — |
| Ind-Swift Laboratories Limited INDSWFTLAB | ₹2,145 Cr | 51.8× | 1.6× | 49.6× | 3.0% | 6.5% | -19.0% |
| Hester Biosciences Limited HESTERBIO | ₹1,957 Cr | 37.6× | 5.8× | 23.3× | 15.4% | 16.7% | 7.7% |
| Tarsons Products Limited TARSONS | ₹1,937 Cr | 98.1× | 3.1× | — | 3.1% | 0.0% | — |
| Shukra Pharmaceuticals Limited SHUKRAPHAR | ₹1,821 Cr | 50.5× | 33.7× | — | 66.4% | 0.6% | — |
| Krsnaa Diagnostics Limited KRSNAA | ₹1,771 Cr | 18.0× | 1.8× | 8.6× | 10.3% | 13.1% | 16.6% |
| NGL Fine-Chem Limited NGLFINE | ₹1,744 Cr | 44.1× | 6.5× | 22.7× | 14.6% | 9.6% | 21.7% |
Gennex trades at a discount to sector peers on P/E (16.4× vs median 44.1×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.